These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 11989610)

  • 1. Anticancer therapy with angiogenesis inhibitors.
    Ghilardi C; Bani MR; Giavazzi R
    Tumori; 2001; 87(6):S14-6. PubMed ID: 11989610
    [No Abstract]   [Full Text] [Related]  

  • 2. Symposium on molecular pathogenesis of respiratory diseases and its clinical implication. 4. Molecular pathogenesis of lung cancer and its molecular targeted therapy.
    Sone S; Shinohara T; Nishioka Y; Yano S
    Intern Med; 2001 Feb; 40(2):167-70. PubMed ID: 11300157
    [No Abstract]   [Full Text] [Related]  

  • 3. Advances in the use of angiogenesis inhibitors in cancer.
    Pinedo HM
    Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080
    [No Abstract]   [Full Text] [Related]  

  • 4. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New molecular target of cancer therapy--angiogenesis regulator VEGF].
    Toi M; Ueno T; Tominaga T
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2202-6. PubMed ID: 9422062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
    Sledge GW
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):104-10. PubMed ID: 12138404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis inhibition in solid tumors.
    Rosen LS
    Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial survival factors as targets for antineoplastic therapy.
    Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
    Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities.
    Siemeister G; Martiny-Baron G; Marmé D
    Cancer Metastasis Rev; 1998 Jun; 17(2):241-8. PubMed ID: 9770121
    [No Abstract]   [Full Text] [Related]  

  • 11. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
    Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
    Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis-research frontiers. A basic science conference of the New York Academy of Medicine.
    Sepp-Lorenzino L; Pan BS
    Expert Opin Investig Drugs; 2000 Apr; 9(4):929-35. PubMed ID: 11185425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF receptor signaling in tumor angiogenesis.
    McMahon G
    Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
    Schlaeppi JM; Wood JM
    Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biological basis for antiangiogenic therapy.
    Giavazzi R; Albini A; Bussolino F; DeBraud F; Presta M; Ziche M; Costa A
    Eur J Cancer; 2000 Oct; 36(15):1913-8. PubMed ID: 11000570
    [No Abstract]   [Full Text] [Related]  

  • 16. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
    Harris AL
    Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of vascular endothelial growth factor in the treatment of solid tumors.
    Margolin K
    Curr Oncol Rep; 2002 Jan; 4(1):20-8. PubMed ID: 11734110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenesis: biology is the foundation for therapy.
    Gerber HP
    Drug Discov Today; 2003 Apr; 8(8):344-6. PubMed ID: 12681937
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.
    Zhu Z; Bohlen P; Witte L
    Curr Cancer Drug Targets; 2002 Jun; 2(2):135-56. PubMed ID: 12188915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of angiogenesis in a clinical perspective.
    Voest EE
    Anticancer Drugs; 1996 Sep; 7(7):723-7. PubMed ID: 8949981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.